Ironwood Pharmaceuticals | IRWD - Current Liabilities


Ironwood Pharmaceuticals reported $236.31M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 361.44M 55.91M Jun/2026
Agios Pharmaceuticals USD 70.22M 11.37M Jun/2026
Akebia Therapeutics USD 160.86M 13.02M Jun/2026
Almirall EUR 323.65M 26.99M Jun/2026
Alnylam Pharmaceuticals USD 1.51B 163.04M Jun/2026
Amarin USD 164.2M 15.45M Jun/2026
Ardelyx USD 109.57M 20.96M Mar/2026
Astellas Pharma JPY 1.23T 16.36B Jun/2026
AstraZeneca USD 31.55B 1.02B Jun/2026
Charles River Laboratories USD 1.13B 41.04M Jun/2026
Coherus Biosciences USD 75.51M 56.82M Jun/2026
Emergent BioSolutions USD 651.3M 12.7M Dec/2023
Halozyme Therapeutics USD 344.44M 18.77M Jun/2026
Incyte USD 1.31B 177.55M Jun/2026
Ironwood Pharmaceuticals USD 236.31M 5.91M Mar/2026
Karyopharm Therapeutics USD 117.3M 25.24M Mar/2026
Lexicon Pharmaceuticals USD 9.9M 10.97M Mar/2026
MacroGenics USD 108.82M 12.88M Jun/2026
Moderna USD 2.53B 139M Jun/2026
Myriad Genetics USD 130.7M 500K Jun/2026
Pacira USD 122.01M 13.22M Jun/2026
PTC Therapeutics USD 771.07M 152.54M Jun/2026
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Sarepta Therapeutics USD 502.91M 3.74M Jun/2026
Takeda JPY 2.76T 335.02B Jun/2026
Ultragenyx Pharmaceutical USD 351M 26M Jun/2026
Vanda Pharmaceuticals USD 145.16M 27.29M Dec/2025